In a mouse model of breast cancer, treatment with Met‐CCL5 (a CCR5 antagonist) for 5 continuous weeks resulted in significant reductions in tumor volume and weight compared with those of control tumors, indicating the activity of Met‐CCL5 against established tumors [166]. This evidence concerns the gene CCL5 and neoplasm.